Comments
Stelis Biopharma (formerly Agila Biotech), a subsidiary of Strides Arcolab Ltd and Pieris AG, a therapeutic protein R&D company, have announced a long-term collaboration for clinical development and commercialisation of multiple novel Anticalin-based protein therapeutics worldwide, primarily focusing on ophthalmology.
The alliance deploys the synergies of Pieris’ innovative drug discovery and early development capabilities with Stelis’ strong bio-manufacturing and clinical development expertise.
Under the terms of the agreement, Pieris will advance each collaborative programme through in vivo proof-of-concept, at which stage Stelis will be responsible for drug manufacturing and advancing the molecule through a first-in-human clinical study. Following positive clinical data, the parties will co-develop programmes under a joint venture.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.